Prostate-specific membrane antigen as a marker of pancreatic cancer cells

Medical Oncology

Volumn 31, Issue 3, 2014, Pages

  Ren, He ^a   Zhang, Huan ^a   Wang, Xiuchao ^a   Liu, Junxiu ^a   Yuan, Zhanna ^a   Hao, Jihui ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Marker; Pancreatic cancer; Prostate specific membrane antigen

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENETICS; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ADENOCARCINOMA; ANTIGENS, SURFACE; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FOLLOW-UP STUDIES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84892944978     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0857-z     Document Type: Article

References (18)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-17.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2009;59(4):225-49.
3. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181-8.
4. Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118-25.
5. Cao KY, Xu L, Zhang DM, Zhang XM, Zhang T, et al. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. Int J Oncol. 2012;40(6):1977-85.
6. Wang W, Mo ZN. Advances in prostate-specific membrane antigen targeted therapies for prostate cancer. Zhonghua Nan Ke Xue. 2010;16(6):547-51.
7. Hull D, Ma J, Singh H, Hossain D, Qian J, Bostwick DG. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases. BJU Int. 2009;104(7):915-8.
8. Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118-25.
9. Bühler P, Wolf P, Elsässer-Beile U. Targeting the prostate-specific membrane antigen for prostate cancer therapy. Immunotherapy. 2009;3:471-81.
10. Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane antigen-based therapeutics. Adv Urol. 2012;2012:973820.
11. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540-7.
12. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192-8.
13. Ren H, Zhao H, Wang T, Yang Y, Han Z, et al. Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura. Clin Immunol. 2006;120(2):205-11.
14. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin N Am J. 2009;23(6):1163-75.
15. Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007;2(3):182-90.
16. Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70(5):562-9.
17. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013;31(2):144-54.
18. Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE. Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate. 2012;72(14):1532-41.